Our disease areas
Transforming drug screening for
neurodegenerative diseases
Mitotype works across disease areas including Parkinson’s, Alzheimer’s, rare diseases, and other neurodegenerative diseases.
Unrivalled
granularity
Backed by more than a decade of expertise, Mitotype offers a library of fully-phenotyped patient lines with robust basal deltas across our entire platform. These models are rigorously validated for responsiveness to diverse therapeutic interventions, whether using small molecules, gene editing, or novel modalities.
By eliminating assay development time, we provide a reliable, high-throughput framework for evaluating your lead candidates in qualified nonclinical models.
Our cell-line library
We have phenotyped, ready-to-go
patient cell lines for:
Parkinson’s
Mutation / disease
Skin
Astrocytes / neurons
LRRK2 G2019S
2
2
PINK1
1 +1 Dec 2026
– +1 Dec 2026
Parkin
4
2 +2 Dec 2026
SNCA triplication
–
1
GBA (E326K & N370S)
3
2 +1 Dec 2026
Sporadic
5
3 +2 Dec 2026
+1 Dec 2026Additional lines expected by the date shown.
Alzheimer’s
Mutation / disease
Skin
Astrocytes / neurons
PSEN1
5
3
Sporadic
18
3 +3 Dec 2026
+1 Dec 2026Additional lines expected by the date shown.
Rare diseases
Mutation / disease
Skin
Astrocytes / neurons
Niemann Picks Disease
2
– +2 Dec 2026
Leigh Syndrome
3
– +2 Dec 2026
Friedrich’s Ataxia
2
2
+1 Dec 2026Additional lines expected by the date shown.
Other diseases
Mutation / disease
Skin
Astrocytes / neurons
Frontotemporal Dementia, Huntington’s, Diabetes Type 1 & 2
12 (3 of each)
– +6 Dec 2026; FTD and HD
+1 Dec 2026Additional lines expected by the date shown.
Controls
Mutation / disease
Skin
Astrocytes / neurons
Healthy Controls
15
6 +6 Dec 2026
+1 Dec 2026Additional lines expected by the date shown.
Don’t see your disease area?
Our portfolio of patient derived phenotyped lines is growing all the time and we are happy to add additional disease areas as required.